Douglas Krulik Buys Shares of PetMed Express, Inc.

Douglas Krulik, the Chief Accounting Officer and Interim CFO of PetMed Express, Inc. (NasdaqGS: PETS), recently purchased 32,500 shares of the company. This insider transaction took place on June 26, 2026, as reflected in the latest filings. The shares were acquired without a disclosed purchase price.

Insider Buying and Selling at PetMed Express, Inc.

Douglas Krulik's recent acquisition of 32,500 shares was not part of a pre-planned transaction, indicating a personal decision to increase his holdings in PetMed Express. Additionally, Nina Capital Holdings Inc. bought 25,000 shares at $1.75 each on June 8, 2026. On the selling side, Gian Fulgoni sold 26,057 shares on January 21, 2026.

Other Institutional Activity in PetMed Express

Renaissance Technologies trimmed its stake in PetMed Express by 40,200 shares, leaving it with 1,186,369 shares valued at about $2.70 million, a 3.3% decrease. Vanguard Capital Management opened a new position with 831,431 shares worth approximately $1.90 million. Federated Hermes added 39,062 shares, raising its holdings to 666,805 shares valued at about $1.52 million, a 6.2% increase. BlackRock added 3,677 shares, bringing its total to 551,677 shares valued at $1.26 million, marking a 0.7% increase.

PetMed Express, Inc. Stock Down 6.4%

On Sunday, shares of PetMed Express traded around $1.76. The company has a market cap of roughly $37.6 million and a forward P/E ratio of -58.67, indicating it is currently not profitable. The stock's 52-week range is between $1.57 and $4.10, with a 50-day moving average of $2.09 and a 200-day moving average of $2.53. The company's current ratio is 0.837, and its quick ratio is 0.448, with a debt-to-equity ratio of 1.849.

Recent Earnings

PetMed Express reported revenue of $179.0 million, which has declined by 15.6%. The company's net margin stands at -32%, and its return on equity is -100.4%. The next earnings report is expected on August 6, 2026.

Analysts Set New Price Targets

Morgan Stanley maintained its sell rating with a price target of $3.20 on April 17, 2025. The consensus target price is $2.15, based on one analyst opinion.

About PetMed Express

PetMed Express, Inc. operates as a pet pharmacy in the United States, offering a variety of prescription and non-prescription medications for pets. Based in Delray Beach, Florida, the company serves pet owners through its website, mobile app, and customer support center. Ms. Leslie C. G. Campbell is the CEO, and the company employs 189 people.

Bottom Line

Douglas Krulik's purchase of shares in PetMed Express highlights insider confidence in the company. Investors often track such transactions for potential signals about the company's prospects. Keep in mind that insider trades are filed after the fact and may not reflect the insider's current position.